| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 1,234 | 1,961 | 1,728 | 1,573 | 1,501 | 1,539 | 1,449 | 1,463 | 1,485 | 1,453 | 1,467 | 1,508 | 1,708 | 1,861 | 1,868 | 1,951 | 1,839 | 1,996 | 2,002 | 1,977 | 1,927 | 2,018 | 1,991 | 1,980 | 1,954 | 2,160 | 2,154 | 2,142 | 2,160 | 2,322 | 2,277 | 2,449 | 2,461 | 2,582 | 2,654 | 2,746 | 2,726 | 2,839 | 2,815 | 2,795 | 2,891 | 3,091 |
| Expenses | 992 | 1,035 | 976 | 1,118 | 1,016 | 1,114 | 1,099 | 1,127 | 1,139 | 1,077 | 1,088 | 1,104 | 1,344 | 1,395 | 1,421 | 1,490 | 1,740 | 1,481 | 1,464 | 1,426 | 1,398 | 1,395 | 1,382 | 1,388 | 1,355 | 1,457 | 1,477 | 1,570 | 2,055 | 1,635 | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 2,019 | 2,146 |
| EBITDA | 242 | 926 | 752 | 455 | 485 | 425 | 350 | 336 | 346 | 376 | 379 | 404 | 364 | 466 | 447 | 461 | 99 | 515 | 538 | 551 | 529 | 623 | 609 | 592 | 599 | 703 | 677 | 572 | 105 | 687 | 665 | 682 | 697 | 782 | 819 | 883 | 864 | 884 | 865 | 900 | 872 | 945 |
| Operating Profit % | 13 % | 45 % | 41 % | 26 % | 31 % | 26 % | 22 % | 20 % | 18 % | 20 % | 22 % | 23 % | 19 % | 24 % | 24 % | 24 % | 5 % | 25 % | 26 % | 26 % | 27 % | 31 % | 30 % | 30 % | 29 % | 31 % | 30 % | 25 % | 2 % | 29 % | 29 % | 28 % | 28 % | 29 % | 30 % | 31 % | 31 % | 31 % | 31 % | 31 % | 31 % | 31 % |
| Depreciation | 60 | 57 | 59 | 59 | 63 | 68 | 69 | 73 | 97 | 80 | 84 | 94 | 151 | 150 | 152 | 156 | 160 | 160 | 163 | 163 | 168 | 161 | 165 | 167 | 165 | 165 | 168 | 167 | 162 | 155 | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 |
| Interest | 47 | 55 | 48 | 43 | 38 | 49 | 51 | 48 | 58 | 56 | 51 | 80 | 121 | 122 | 126 | 133 | 123 | 122 | 116 | 111 | 102 | 102 | 92 | 91 | 73 | 68 | 71 | 62 | 57 | 55 | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 |
| Profit Before Tax | 155 | 875 | 681 | 377 | 410 | 346 | 253 | 245 | 244 | 266 | 272 | 259 | 134 | 232 | 205 | 275 | -150 | 279 | 296 | 319 | 293 | 402 | 384 | 357 | 383 | 484 | 472 | 357 | -87 | 532 | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 |
| Tax | 25 | 225 | 172 | 87 | 126 | 54 | 46 | 16 | 38 | 78 | 68 | 201 | -94 | 69 | 26 | 29 | 2 | 63 | 52 | 68 | -21 | 81 | 74 | 60 | 59 | 154 | 156 | 108 | 31 | 178 | 151 | 127 | 146 | 153 | 173 | 188 | 182 | 199 | 208 | 188 | 167 | 190 |
| Net Profit | 130 | 650 | 509 | 290 | 284 | 292 | 207 | 229 | 206 | 188 | 204 | 58 | 228 | 163 | 179 | 246 | -152 | 216 | 244 | 251 | 314 | 321 | 310 | 297 | 324 | 330 | 316 | 249 | -118 | 354 | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 |
| EPS in ₹ | 7.70 | 38.40 | 30.01 | 17.19 | 16.82 | 17.28 | 12.25 | 13.47 | 12.17 | 11.08 | 12.07 | 3.37 | 13.55 | 9.66 | 10.57 | 14.50 | -8.95 | 12.74 | 14.48 | 14.77 | 18.56 | 18.98 | 18.32 | 17.52 | 19.16 | 19.53 | 18.63 | 14.75 | -6.97 | 20.90 | 9.22 | 8.63 | 8.48 | 11.18 | 11.39 | 13.10 | 13.27 | 13.51 | 13.37 | 14.88 | 14.71 | 16.19 |
Torrent Pharmaceuticals
Torrent Pharmaceuticals
3,557.70
-41.60
(-1.16%)
Key Fundamentals
Market Cap
1,20,408.73 Cr
EPS
56.47
PE Ratio
60.85
Dividend Yield
0.17 %
Industry
Healthcare 52 Week High
3,787.90
52 Week Low
2,886.45
PB Ratio
16.05
Debt to Equity
0.50
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from26 analysts
Actual
Company News
View All News
Torrent Pharma Plans Rs 14,000 Crore Bond Issue Following JB Chemicals Acquisition Approval
6 days ago
6 days agoTorrent Pharmaceuticals will proceed with a bond sale worth up to Rs 14,000 crore ($1.6 billion) after receiving competition regulator approval for its acquisition of JB Chemicals & Pharmaceuticals. The bond issue represents the largest rated issuance this financial year and follows a trend of acquisitions being funded through domestic bond offerings. The company plans to sell multiple tenor bonds with maturities ranging from 15 to 42 months, aiming to close the sale before mid-December. Barclays and Standard Chartered Bank are among the arrangers for the bond sale. India Ratings and Research has assigned an AA+ rating to the bond issue, expecting the merger to elevate Torrent Pharma's market position from seventh to fifth largest in the Indian pharmaceutical market by market share.
The Competition Commission of India approved Torrent Pharmaceuticals' acquisition of a majority stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications by both companies. The deal involves acquiring a 46.39% stake from promoters Tau Investment Holdings (KKR affiliate) for Rs 11,917 crore, a 2.80% stake from employees for Rs 719 crore, and an open offer for an additional 26% stake worth Rs 6,842.8 crore. The total transaction value of Rs 19,500 crore makes it the second-largest acquisition in India's pharmaceutical sector after Sun Pharma's 2015 Ranbaxy acquisition. Upon completion, the acquisition will involve JB Chemicals' amalgamation into Torrent Pharma, potentially making Torrent India's second-most valued pharma company. Torrent Pharma operates with annual revenues exceeding Rs 11,500 crore, while JB Chemicals specializes in pharmaceutical formulations, APIs, and CDMO services.
The Competition Commission of India approved Torrent Pharmaceuticals' proposed acquisition of JB Chemicals and Pharmaceuticals in a ₹19,500-crore deal, subject to voluntary modifications. The transaction involves Torrent acquiring a 46.39% stake from promoters Tau Investment Holdings (KKR affiliate) for ₹11,917 crore, an additional 2.80% from employees for ₹719 crore, and making an open offer for 26% stake totaling ₹6,842.8 crore. Following completion, JB Pharma will merge into Torrent, making Torrent India's second most valued pharma company. This represents the second biggest pharma sector deal ever, behind Sun Pharmaceutical's 2015 Ranbaxy acquisition. Torrent Pharma has annual revenues exceeding ₹11,500 crore and is part of the Torrent Group with ₹45,000 crore in group revenues. CCI also separately approved the acquisition of up to 15% shareholding in Edelweiss Asset Management and Edelweiss Trusteeship Company by Setu AIF Trust, Konark Trust and MMPL Trust.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,680.40 | #1 4,03,184.25 | 39.61 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 67.74 | |
6,569.00 | 1,74,386.31 | 74.94 | 9,712.00 | 18.67 | 2,191 | 26.74 | 60.77 | |
1,561.20 | 1,26,106.57 | 23.71 | 28,409.50 | 7.12 | 5,291 | 9.88 | 52.88 | |
3,557.70 | #4 1,20,408.73 | #9 60.85 | #9 11,539.40 | #9 6.99 | #10 1,911 | #4 19.91 | 54.44 | |
2,424.60 | 1,00,077.42 | 52.75 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.93 | |
1,192.90 | 99,561.08 | #1 18.22 | 33,741.20 | 16.73 | 5,725 | -0.38 | 45.01 | |
984.00 | 99,013.42 | 21.40 | 23,511.00 | 18.55 | 4,615 | 2.60 | 51.23 | |
1,927.70 | 88,048.57 | 24.01 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 51.72 | |
5,462.50 | 65,312.38 | 28.37 | 13,458.30 | 3.70 | 2,216 | 21.39 | 55.26 | |
1,093.50 | 63,510.66 | 19.23 | 32,345.60 | 9.43 | 3,484 | -10.24 | 55.31 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
6.99 %
Net Income Growth
15.39 %
Cash Flow Change
-20.85 %
ROE
4.22 %
ROCE
1.42 %
EBITDA Margin (Avg.)
2.17 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Fixed Assets | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,122 | 8,138 | 7,947 |
| Current Assets | 4,051 | 4,688 | 4,880 | 5,262 | 5,038 | 4,979 | 5,522 | 5,165 | 5,314 | 5,612 | 5,623 |
| Capital Work in Progress | 678 | 1,042 | 520 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 |
| Other Assets | 4,095 | 4,378 | 4,691 | 5,249 | 5,403 | 5,763 | 5,940 | 5,821 | 5,926 | 6,389 | 6,409 |
| Total Liabilities | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Current Liabilities | 2,824 | 3,286 | 2,738 | 5,202 | 5,165 | 5,454 | 4,892 | 4,415 | 5,447 | 5,425 | 4,717 |
| Non Current Liabilities | 2,589 | 2,278 | 2,613 | 4,418 | 4,231 | 3,732 | 3,346 | 2,732 | 3,367 | 2,779 | 2,682 |
| Total Equity | 2,491 | 3,495 | 4,351 | 4,623 | 4,724 | 4,823 | 5,837 | 5,953 | 6,198 | 6,856 | 7,591 |
| Reserve & Surplus | 2,406 | 3,410 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,422 |
| Share Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -90 | 438 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 |
| Investing Activities | -2,113 | -870 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 |
| Operating Activities | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 |
| Financing Activities | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Jul 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 68.31 % | 68.31 % | 68.31 % | 68.31 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.14 % | 14.22 % | 14.46 % | 16.17 % | 16.31 % | 16.09 % | 15.92 % |
| DIIs | 6.53 % | 6.71 % | 6.76 % | 6.78 % | 7.52 % | 7.82 % | 7.76 % | 8.89 % | 8.87 % | 9.00 % | 8.31 % | 7.16 % | 6.44 % | 7.26 % | 7.27 % | 7.08 % | 8.35 % | 8.35 % | 8.65 % | 9.28 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.89 % | 7.72 % | 7.58 % | 7.29 % | 7.25 % | 7.10 % | 7.13 % | 4.59 % | 4.73 % | 4.47 % | 4.38 % | 4.25 % | 4.15 % | 4.09 % | 3.98 % | 4.34 % | 4.61 % | 4.51 % | 4.44 % | 4.08 % |
| Others | 14.33 % | 14.33 % | 14.42 % | 14.68 % | 13.98 % | 13.83 % | 13.86 % | 15.27 % | 15.16 % | 15.28 % | 16.07 % | 17.34 % | 18.16 % | 3.27 % | 3.28 % | 2.87 % | 2.56 % | 2.52 % | 2.50 % | 2.41 % |
| No of Share Holders | 0 | 72,616 | 64,525 | 64,309 | 67,205 | 63,229 | 62,933 | 64,557 | 67,866 | 63,831 | 61,572 | 69,612 | 69,117 | 71,154 | 74,765 | 79,848 | 85,035 | 86,005 | 81,856 | 78,226 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 14 | 14 | 17 | 32 | 35 | 48 | 22 | 28 | 32 |
| Dividend Yield (%) | 0.00 | 2.24 | 1.44 | 1.72 | 2.51 | 2.51 | 3.12 | 0.85 | 0.87 | 0.89 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 07 Nov 2025 |  Quarterly Result Announcement | NA | 07 Nov 2025 | 3,578.35 | 3,599.30 |
| 16 Feb 2021 |  Dividend | ₹ 20.00 /share | 15 Feb 2021 | 1,376.03 | 1,303.15 |
| 18 Jun 2021 | Dividend | ₹ 15.00 /share | 17 Jun 2021 | 1,382.38 | 1,476.95 |
| 03 Feb 2022 | Dividend | ₹ 25.00 /share | 02 Feb 2022 | 1,552.43 | 1,367.98 |
| 06 Jun 2022 | Dividend | ₹ 15.00 /share | 03 Jun 2022 | 1,296.25 | 1,390.33 |
| 06 Jun 2022 | Dividend | ₹ 8.00 /share | 03 Jun 2022 | 1,296.25 | 1,390.33 |
| 11 Jul 2022 |  Bonus | 1:1 | 08 Jul 2022 | 1,441.88 | 1,466.70 |
| 03 Feb 2023 | Dividend | ₹ 14.00 /share | 03 Feb 2023 | 1,584.65 | 1,541.05 |
| 23 Jun 2023 | Dividend | ₹ 8.00 /share | 23 Jun 2023 | 1,705.95 | 1,862.65 |
| 12 Feb 2024 | Dividend | ₹ 22.00 /share | 12 Feb 2024 | 2,512.50 | 2,657.35 |
| 21 Jun 2024 | Dividend | ₹ 6.00 /share | 21 Jun 2024 | 2,691.80 | 2,858.10 |
| 23 Jul 2024 |  Annual General Meeting | NA | 23 Jul 2024 | 2,840.45 | 3,028.80 |
| 25 Oct 2024 | Quarterly Result Announcement | NA | 25 Oct 2024 | 3,557.25 | 3,317.25 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 3,274.45 | 3,266.20 |
| 01 Feb 2025 | Dividend | ₹ 26.00 /share | 31 Jan 2025 | 3,266.20 | 3,259.20 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 3,237.70 | 3,302.80 |
| 20 Jun 2025 | Dividend | ₹ 6.00 /share | 20 Jun 2025 | 3,302.80 | 3,164.00 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 3,521.85 | 3,603.80 |
| 28 Jul 2025 | Annual General Meeting | NA | 28 Jul 2025 | 3,334.10 | 3,603.80 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation2 days ago
2 days agoBoard Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20152 days ago
2 days agoAnnouncement Under Regulation 20 Of SEBI LODR8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Credit RatingOct 07, 2025
Oct 07, 2025Announcement under Regulation 30 (LODR)-Credit RatingOct 07, 2025
Oct 07, 2025Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Oct 04, 2025
Oct 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 03, 2025
Oct 03, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Redemption Of Commercial Papers Issued Under ISIN INE685A14153Sep 26, 2025
Sep 26, 2025Intimation Regarding Issue Of Commercial PapersSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 23, 2025
Sep 23, 2025Redemption Of Commercial Papers Issued Under ISIN: INE685A14146Sep 18, 2025
Sep 18, 2025Intimation Regarding Issue Of Commercial PapersSep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2025
Aug 05, 2025Announcement Under Reg 30Aug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 28, 2025
Jul 28, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 28-Jul-25Jul 28, 2025
Jul 28, 2025Results For Quarter Ended 30-Jun-25Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Letter To Shareholders - Integrated Annual Report FY 2024-25Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Jul 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Jul 04, 2025Reg. 34 (1) Annual Report.Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 29, 2025
Jun 29, 2025Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations).Jun 29, 2025
Jun 29, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14120Jun 27, 2025
Jun 27, 2025Intimation Regarding Issue Of Commercial PapersJun 26, 2025
Jun 26, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14138Jun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesJun 20, 2025
Jun 20, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
May 23, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Mutual Fund Holdings
HDFC Large Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Axis Quant Fund Direct-Growth 
Franklin India Large & Mid Cap Fund Direct-Growth 
Nippon India Arbitrage Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
DSP Arbitrage Fund Direct - Growth 
ICICI Prudential Nifty Next 50 Index Direct-Growth 
Baroda BNP Paribas Business Conglomerates Fund Direct-Growth 
Aditya Birla Sun Life Quant Fund Direct-Growth 
HSBC Arbitrage Fund Direct-Growth 
UTI Nifty Next 50 Index Fund Direct - Growth 
Bandhan Arbitrage Fund Direct-Growth 
Canara Robeco Focused Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 54.44
ATR(14)
Less Volatile 63.54
STOCH(9,6)
Neutral 53.29
STOCH RSI(14)
Neutral 69.45
MACD(12,26)
Bullish 6.24
ADX(14)
Weak Trend 17.13
UO(9)
Bearish 45.23
ROC(12)
Uptrend And Accelerating 1.88
WillR(14)
Neutral -42.10
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
Chairperson NameSamir Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
